pISSN 1226-6051
eISSN 2508-786X

Fig. 3.

Download original image
Fig. 3. Objective response rate of programmed death-ligand 1 antagonist. Patients treated with pembrolizumab were well responded better compared patients with nivolumab at 30 days after treatment, however no difference in objective response rate was observed after that point (*p<0.05).
Korean J Clin Pharm 2020;30:11-8 https://doi.org/10.24304/kjcp.2020.30.1.11
© 2020 Korean J Clin Pharm